bioRxiv Science⌕ Search

Biology subjects

Hottiger, M. O.

Publications and source records attributed to Hottiger, M. O..

7 recordsLinked to original sources

PARP16 protects against cardiac hypertrophic response by ADP-ribosylation-dependent inhibition of NFAT transcription factor

Mono-ADP-ribosylation is a post-translational modification that regulates diverse cellular processes. PARP16 is an endoplasmic reticulum-associated mono-ADP-ribosyltransferase implicated in stress-response signalling; however, its role in cardiac remodelling and dysfunction has not been fully defined. Our results suggest that PARP16 expression was reduced in human heart failure samples. Deletion of PARP16 in several mice models promoted ventricular dilatation, fibrosis, fetal gene reactivation, and systolic dysfunction, whereas cardiomyocyte-specific overexpression of PARP16 attenuated isoproterenol-induced remodelling in mice. Transcriptomic profiling and functional studies identified NFAT signalling as a major downstream pathway activated following PARP16 deficiency. Specifically, loss of PARP16 increased nuclear accumulation, promoter occupancy, and transcriptional activity of NFAT1. Mechanistically, PARP16 interacted with NFAT1 and suppressed NFAT-dependent transcription through a catalytic activity-dependent mechanism. Proteomic, structural, and functional analyses identified E398 and T533 residues of NFAT1 associated with PARP16-mediated regulation. Furthermore, pharmacological inhibition of NFAT improved cardiac function and remodelling in PARP16-deficient mice. These findings indicate that PARP16 acts as a negative regulator of NFAT signalling and contributes to protection against adverse cardiac remodelling.

cell biology↗

PARP6-dependent vimentin ADP-ribosylation prevents myofibroblast activation in cardiac fibrosis

Cardiac fibrosis is a central driver of adverse remodeling during heart failure, yet the post-translational regulation of myofibroblast activation remains poorly defined. Here, we identified PARP6 as a mono-ADP-ribosyltransferase that repressed myofibroblast activation through the ADP-ribosylation of vimentin. PARP6 expression was reduced in failing human hearts and Parp6 haploinsufficiency in mice was sufficient to induce cardiac fibrosis. At the cellular level, PARP6 ADP-ribosylated vimentin thereby limiting actin stress fiber formation. Mechanistically, PARP6 inhibition enhanced RhoA activation and vimentin-RhoA complex formation, thus activating the RhoA-ROCK-LIMK-cofilin pathway. Consistently, Parp6 haploinsufficiency was associated with increased cofilin phosphorylation in mice hearts. In primary cardiac fibroblasts, PARP6 inhibition promoted RhoA-dependent actin stress fiber accumulation and induced myofibrotic protein expression. Together, these findings define a PARP6-vimentin(ADP-ribosylation)-RhoA axis that restrained contractility-driven fibroblast activation, indicating a cardioprotective role of PARP6 with potential therapeutic relevance for fibrotic heart disease.

molecular biology↗

PARP14 mediated SQSTM1/p62 cysteine ADP-ribosylation is counteracted by the SARS-CoV-2 macrodomain

Interferon-induced ADP-ribosyltransferases are emerging regulators of cellular innate immunity, yet the relevant substrates and downstream effects remain incompletely defined. Here, we mapped the PARP14-dependent ADP-ribosylome in lung epithelial cancer cells and identified the selective autophagy adaptor SQSTM1/p62, along with multiple innate immune regulators, as IFN-dependent MARylation substrates. Site-resolved analysis revealed that PARP14-dependent MARylation is strongly enriched on cysteine residues, including defined cysteine acceptor sites within p62. PARP14-dependent MARylation is localized to cytoplasmic p62 foci that colocalize with diverse ubiquitin species. Furthermore, our results indicate that TRIM21 limits the autophagic degradation of p62, suggesting that the identified p62 foci may have degradation-independent roles. Consistent with this, both PARP14 and p62 support inflammatory gene expression, linking PARP14-dependent MARylation to innate immune regulation. Together, our findings identify p62 foci as sites of PARP14-dependent ADP-ribosylation and suggest a functional link between interferon signaling, ubiquitin-associated protein assemblies, and MARylation-dependent innate immune regulation.

molecular biology↗

PRAMEL7/CUL2 axis regulates NuRD stability to establish ground-state pluripotency in embryonic stem cells

Pluripotency is established in E4.5 preimplantation epiblast. Embryonic stem cells (ESCs) represent the immortalization of pluripotency, however, they only partially resemble the gene expression signature of developmental ground-state. Induced PRAMEL7 expression, a protein highly expressed in the ICM but lowly expressed in ESCs, reprograms developmentally advanced ESC+serum into ground-state pluripotency by causing DNA hypomethylation and gene expression signature close to developmental ground-state. However, how PRAMEL7 reprograms gene expression remains elusive. Here we show that PRAMEL7 associates with Cullin2 (CUL2) and this interaction is required to establish ground-state gene expression. PRAMEL7 recruits CUL2 to chromatin and targets for proteasomal degradation regulators of repressive chromatin, including NuRD complex. PRAMEL7 antagonizes NuRD-mediated repression of genes implicated in pluripotency by decreasing NuRD stability and promoter association in a CUL2-dependent manner. Our data link proteasome degradation pathways to ground-state gene expression, offering insights to generate in vitro models to reproduce the in vivo ground-state pluripotency.

developmental biology↗

Tankyrase-mediated ADP-ribosylation is a novel regulator of TNF-induced death

Tumor necrosis factor (TNF) is an inflammatory cytokine that, upon binding to its receptor TNFR1, can drive cytokine production, cell survival, or cell death and is a major component of an organisms anti-pathogen repetoire1,2. TNF stimulation leads to the formation of two distinct signalling complexes, a well-defined membrane bound complex (complex 1), and a less well characterised cytosolic death inducing complex (complex 2). Using mass spectrometry, we identified the ADP-ribosyltransferase, tankyrase-1 (TNKS1/TNKS/ARTD5/PARP5a) as a novel native complex 2 component. Following a TNF-induced death stimulus TNKS1 is recruited to complex 2, resulting in complex 2 poly(ADP-ribosyl)ation (PARylation). Tankyrase inhibitors sensitise cells to TNF-induced death, which is correlated with increased complex 2 assembly. Tankyrase-mediated PARylation promotes recruitment of the E3 ligase RNF146 and RNF146 deficiency or proteasome inhibition results in increased levels of complex 2, suggesting that RNF146 causes proteasomal degradation of complex 2. Several viruses express ADP-ribose binding macrodomain proteins, and expression of the SARS-CoV-2 or VEEV macrodomain markedly sensitises cells to TNF-induced death. This suggests that ADP-ribosylation serves as yet another mechanism to detect pathogenic interference of TNF signalling and retaliate with an inflammatory cell death.

cell biology↗

Development of a mass-spectrometry based method for the identification of the in vivo whole blood and plasma ADP-ribosylomes

Blood and plasma proteins are heavily investigated as biomarkers for different diseases. However, the post-translational modification states of these proteins are rarely analyzed since blood contains many enzymes that rapidly remove these modification after sampling. In contrast to the well-described role of protein ADP-ribosylation in cells and organs, its role in blood remains mostly uncharacterized. Here, we discovered that plasma phosphodiesterases and/or ADP-ribosylhydrolases rapidly demodify in vitro ADP-ribosylated proteins. Thus, to identify the in vivo whole blood and plasma ADP-ribosylomes, we established a novel mass-spectrometry based workflow that was applied to blood samples collected from LPS-treated pigs (Sus scrofa), which serves as a model for human systemic inflammatory response syndrome. These analyses identified 60 ADP-ribosylated proteins, 17 of which were ADP-ribosylated plasma proteins. This new protocol provides an important step forward for the rapidly developing field of ADP-ribosylation and defines the blood and plasma ADP-ribosylomes under both healthy and disease conditions.

molecular biology↗

Discovery of compounds inhibiting the ADP-ribosyltransferase activity of pertussis toxin

Targeted pathogen-selective approach to antibiotic development holds promise to minimize collateral damage to the beneficial microbiome. The AB5-topology pertussis toxin (PtxS1-S5, 1:1:1:2:1) is a major virulence factor of Bordetella pertussis, the causative agent of the highly contagious respiratory disease whooping cough. Once internalized into the host cell, PtxS1 ADP-ribosylates -subunits of the heterotrimeric Gi-superfamily, thereby disrupting G-protein-coupled receptor signaling. Here, we report the discovery of the first small molecules inhibiting the ADP-ribosyltransferase activity of pertussis toxin. We developed protocols to purify mg-levels of truncated but highly active recombinant B. pertussis PtxS1 from Escherichia coli and an in vitro high throughput-compatible assay to quantify NAD+ consumption during PtxS1-catalyzed ADP-ribosylation of Gi. Two inhibitory compounds (NSC228155 and NSC29193) with low micromolar IC50-values (3.0 {micro}M and 6.8 {micro}M) were identified in the in vitro NAD+ consumption assay that also were potent in an independent in vitro assay monitoring conjugation of ADP-ribose to Gi. Docking and molecular dynamics simulations identified plausible binding poses of NSC228155 and in particular of NSC29193, most likely owing to the rigidity of the latter ligand, at the NAD+-binding pocket of PtxS1. NSC228155 inhibited the pertussis AB5 holotoxin-catalyzed ADP-ribosylation of Gi in living human cells with a low micromolar IC50-value (2.4 {micro}M). NSC228155 and NSC29193 might prove useful hit compounds in targeted B. pertussis-selective drug development.

microbiology↗